Aviva Systems Biology provides their customers with an extensive collection of quality antibodies for research and diagnostic applications. Aviva currently offers antibodies to more than 7,000 different protein targets due to their high throughput antibody production releases more than 200 new antibodies every month. Aviva's focus is antibodies to key targets in areas of transcription, epigenetics and cell signalling. Aviva's antibody collection includes unique antibody content to many targets that are not commercially available elsewhere. We place our emphasis on family-oriented antibody production has yielded antibodies to most members of key protein families such as Transcription Factors, Transcription Regulators, RNA Binding Proteins, Ion Channels, and Cell Membrane target proteins.
Aviva also has a rich pipeline of an additional 17,000 antibodies that are currently undergoing extensive western blot characterization and validation using a panel of 6 tissues and 6 cell lines. We anticipate releasing several thousand new antibody products in the year ahead as Aviva's high throughput processing team characterizes these candidate new products.